Eye Cancer Market Expected to Grow to $35.7 Billion by 2035

Eye cancer market was valued at $16.2 billion in 2025 and is projected to reach $35.7 billion by 2035, growing at a CAGR of 8.3% during the forecast period (2026-2035). The incidence of eye cancer, although relatively low compared to other oncology indications, is showing a gradual increase across several regions, thereby contributing to market expansion. In the United States, the American Cancer Society estimates approximately 3,200 new cases of primary eye and orbit cancers in 2026, along with around 530 associated mortality, indicating a steady disease burden. Similarly, in the United Kingdom, nearly 850 cases are diagnosed annually, reinforcing the presence of a consistent patient pool in developed markets. While primary eye cancers remain rare, the growing identification of both primary and secondary ocular malignancies is improving overall case detection rates. Emerging economies such as India also contribute significantly to global incidence, with nearly 1,000 cases reported, a large proportion of which occur in children, particularly in the 0–4 age group due to conditions such as retinoblastoma. Furthermore, demographic factors such as aging populations are increasing the prevalence of adult eye cancers, particularly melanoma of the eye. Advancements in diagnostic capabilities and improved awareness are also leading to earlier and more frequent detection of cases that may have previously gone undiagnosed. Although the overall incidence remains low in comparison to other cancers, the consistent rise in diagnosed cases across both developed and developing regions is supporting demand for treatment and diagnostic solutions. This trend is further amplified by improved access to healthcare services and oncology infrastructure. Consequently, the increasing incidence of eye cancer, combined with better detection and demographic shifts, acts as a moderate yet steady driver for the growth of the global eye cancer market.

Browse the full report description of “Eye Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Uveal Melanoma, Retinoblastoma, Ocular Lymphoma, Conjunctival Melanoma, and Eyelid Cancer), by Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), and by End-User (Hospitals, Specialty Eye Clinics, and Ambulatory Surgical Centers), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/eye-cancer-market

Strategic Collaborations and Licensing Deals

Major players in the global eye cancer market include Immunocore Holdings plc, Novartis AG, Pfizer Inc., Merck & Co., Inc., and Teva Pharmaceuticals. These companies are driving innovation across multiple treatment modalities for ocular malignancies.

• In September 2025, Servier and IDEAYA Biosciences announced an exclusive license agreement granting Servier the regulatory and commercial rights to darovasertib outside the U.S. Darovasertib, a selective PKC inhibitor for uveal melanoma, is being developed across multiple global clinical trials, including Phase 3 studies in neoadjuvant, adjuvant, and metastatic settings. Under the deal, IDEAYA will receive $210 million upfront, up to $320 million in milestones, and royalties on net sales, while both companies collaborate on development and cost sharing.

• In January 2022, the FDA approved tebentafusp-tebn, the first treatment for metastatic uveal melanoma in adults, demonstrating a survival benefit in Phase 3 trials. Tebentafusp-tebn is a novel TCR-based immunotherapy that redirects T cells to target gp100-expressing cancer cells, marking a breakthrough in solid tumor treatment. The therapy is effective only in patients with the HLA-A*0201 type, representing about 40–50% of uveal melanoma patients.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Cancer Type
• Treatment Type
• End-User

• Competitive Landscape – Immunocore Holdings plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., and Teva Pharmaceuticals Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Eye Cancer Market Report Segment

By Cancer Type

• Uveal Melanoma
• Retinoblastoma
• Ocular Lymphoma
• Conjunctival Melanoma
• Eyelid Cancer

By Treatment Type

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy

By End-User

• Hospitals
• Specialty Eye Clinics
• Ambulatory Surgical Centers

Global Eye Cancer Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/eye-cancer-market